Serenity is developing antibody mimetics that facilitate targeted protein degradation, providing a precise method for eliminating disease-causing proteins. This technology addresses the challenge of selectively degrading proteins implicated in various diseases, offering potential therapeutic benefits in areas such as cancer and neurodegeneration.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases are caused by specific proteins that are difficult to target with traditional drugs. Selectively removing these disease-causing proteins is a challenge, as current methods may lack precision or have off-target effects.
Solution
Serenity is engineering antibody mimetics designed to induce targeted protein degradation, offering a precise method for eliminating disease-causing proteins. These mimetics bind to a target protein and recruit an E3 ubiquitin ligase, tagging the protein for degradation by the proteasome. This approach allows for selective removal of specific proteins implicated in various diseases, potentially minimizing off-target effects compared to traditional small molecule inhibitors. The technology aims to provide therapeutic benefits in areas such as cancer and neurodegeneration by addressing the root cause of the disease at the protein level.
Target Audience
The primary customers are pharmaceutical companies and research institutions focused on developing targeted therapies for diseases driven by specific proteins.
Features
- Antibody mimetics engineered for high affinity and specificity to target proteins
- Modular design allows for rapid generation of mimetics against diverse protein targets
- Recruit endogenous E3 ubiquitin ligases to induce proteasomal degradation
- Tunable degradation kinetics for precise control over target protein levels
- Potential for improved safety profiles compared to traditional inhibitors